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Abstract
This study was performed in acute stroke patients in the Turkish population to determine the frequency of the A1166C polymorphism in the
AT1 gene and to examine the role of this polymorphism in acute stroke development. In this study, 257 genomic DNA samples were analysed
(from 206 acute stroke patients and 51 healthy individuals). Genomic DNA was prepared from peripheral blood using the salt-extraction
method. The presence of the A1166C polymorphism in the AT1 gene was determined using the polymerase chain reaction (PCR)-restriction
fragment length polymorphism (RFLP) method. PCR products were separated by 2% agarose gel electrophoresis and visualized by a charge-
coupled device (CCD) camera. In this study, the allele frequency at the A1166C position was 92% A and 8% C for control and 97% A and 3% C
for patients. This difference in allele frequency between the control group and the patient group was not statistically significant. However, geno-
type and allele frequencies showed a significant difference (P < 0.001) in the control and the patient groups. The results of this study show no
relationship between the A1166C polymorphism in the AT1 gene and acute stroke in the Turkish population.
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Introduction
Stroke is a common, multifactorial cardiovascular disease. A stroke
event is the result of a complex interplay between traditional risk fac-
tors (i.e. hypertension, diabetes and smoking), environmental expo-
sures and genetic factors [1].
The genetic basis of some metabolic and coagulation disorders
predisposing to stroke is known, but the molecular basis of the
genetic predisposition in the majority of stroke patients remains
unknown. Genes that influence the renin–angiotensin–aldosterone
system (RAAS) are potentially aetiological candidates for causing
hypertension, stroke and cardiovascular disease [2].
The RAAS is important for cerebrovascular research because it
influences blood pressure, vasoconstriction, thrombosis and vessel
wall damage. Renin, released from the kidney, cleaves angiotensino-
gen (AT) to angiotensin I, which then is modified by angiotensin-con-
verting enzyme (ACE) to angiotensin II (ATII) [3–5]. Angiotensin II is
a major effector of the RAAS and is involved in vasoconstriction, aldo-
sterone secretion, renal function and cardiovascular proliferation.
Two kinds of angiotensin II receptors, type 1 and type 2, have been
identified, and most of the known actions of angiotensin II are medi-
ated by the angiotensin II type 1 receptor (AT1R), which is largely
associated with human cardiovascular and renal diseases. AT1R is a
G protein-coupled receptor, which exerts its actions by activating
phospholipase C, tyrosine kinases or non-receptor tyrosine kinases
[6–8]. The human AT1R (Accession Number: P30556) gene is more
than 50 kb in length and contains five exons and four introns [6–9].
ATR1 is expressed in different organs including the heart, skeletal
muscle, brain, liver, lung and adrenal gland [5–7]. Angiotensin II acts
mainly via the angiotensin II type I receptor (AT1R) as a potent
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vasoconstrictor, which regulates vascular tone and systemic blood
pressure [10, 11].
The A 1166 ? C polymorphism of the AT1 gene has been
described with either an adenine (A) or a cytosine (C) base (A/C trans-
version) in position 1166 of the 3′ untranslated region of the gene [9,
10, 12].
Many polymorphisms in genes of the RAAS pathway have been
identified [8]. AT1R A1166C has been postulated as a candidate sus-
ceptibility factor for stroke [13–15]. Recent findings suggest that the
A1166C polymorphism of the angiotensin II type 1 receptor gene is
associated with ischaemic stroke [16].
Any possible association of the ACE and AT1R genotype with
stroke pathogenesis should be important, particularly as hypertension
is a major risk factor for stroke [17].
In the past few years, the genetic polymorphism (A1166C) of
AT1R has been proved to be related to the stroke risk in several popu-
lations [13, 14, 18–22]. However, some other studies failed to find an
association between AT1R A1166C polymorphisms and stroke [23,
24]. Therefore, this study was performed to determine the genotypic
frequency of the A1166C polymorphism of the AT1 gene in acute
stroke patients in Turkish population with the aim of examining the
role of this polymorphism in stroke development.
Materials and methods
This study included 206 acute stroke patients (94 women and 112 men;
mean age 62.98  12.69) and 51 controls (35 women and 16 men;
mean age 57.98  8.68) recruited by the medical faculty in the Neurol-
ogy Department at Eskisehir Osmangazi University. Eskisehir, Turkey.
The study population was genetically homogeneous and native to Tur-
key. Informed consent was obtained from each patient in accordance
with a study protocol approved by the ethics committee of Eskisehir Os-
mangazi University. Acute stroke patients were separated into six sub-
groups according to the computed tomography (CT) and magnetic
resonance imaging (MRI) results: large vessel disease (macrovascular
disease), small vessel disease (lacunar infarction) cardioembolism
(cardiac disease), transient ischaemic attacks (TIA), other ischaemic
strokes and haemorrhage (Bleeding). Controls were selected from the
individuals without personal and family history of stroke.
DNA was extracted from 10 ml of venous blood, anti-coagulated with
1.6 mg/ml ethylenediaminetetraacetic acid (EDTA) by salt-extraction
method and stored at +4°C overnight. After the plasma was removed,
50 ml lysis buffer was added to the pellet. This mixture was centrifuged
at 778 9 g at +4°C for 15 min. Supernatant was removed and 20 ml
lysis buffer was added to the pellet and centrifuged. Supernatant was
removed and 5 ml natrium EDTA, 500 ml sodium dodecyl sulphate
(SDS), 100 ml proteinase-K were added to the pellet. After overnight
incubation at 37°C, 2 ml of NaCl was added and centrifuged at
2383 9 g at +4°C for 20 min. The obtained supernatant was centri-
fuged at 2383 9 g at +4°C for 15 min and equal volume of 2-propanol
was added. DNA was seen at the end of this step. Then, the DNA was
washed in the 70% alcohol and put in the vial. The alcohol was evapo-
rated and 500 ml Tris-EDTA was added to the DNA, and incubated at
50°C overnight [25]. The DNA samples were amplified using the prim-
ers, PCR mixture (one sample) and PCR conditions described below
(Table 1).
PCR products, 410 bp in length, were cut by 5 U of the HindIII
restriction enzyme (Boehringer Mannheim, Mannheim, Germany)
according to the manufacturer’s instructions. PCR fragments were sepa-
rated by 2% agarose gel (63103; Sigma-Aldrich Co., St Louis, MO,
USA) electrophoresis with 1 mg/ml ethidium bromide and viewed by a
charge-coupled device (CCD) camera. The results were evaluated via gel
analysis software (LabWorks, Cambridge, UK). After HindIII restriction
analysis, the following three genotypes were determined: AA (410 bp),
AC (410, 219, and 191 bp), and CC (219 and 191 bp; Fig. 1).
Statistical analysis was performed using the SPSS 15.0 (Statistical
Package for Social Sciences) software package. Continuous variables
were expressed as the means  SE. Alleles and genotype frequencies
between patients and controls were compared by the chi-squared test.
Some physiological and clinical parameters of patients and controls
were also analysed by the chi-squared test. The ANOVA and chi-squared
test were used to compare some physiological and clinical parameters
of patients and controls, according to the AT1 gene A1166C polymor-
Table 1 PCR mixture (one sample) and PCR condition
PCR mixture
PCR condition
Step Time Temperature (+) Cycles
Primer 1 2 pmol Sense: 5′- AGAAGCCTGCACCATGTTTTGAG -3′
Primer 2 2 pmol Antisense: 5′- CCTGTTGCTCCTCTAACGATTTA -3′
dNTP mix 0.2 mM 4 min. 94°C
PCR buffer Amplification 30
Tris-HCl 10 mM Denaturation 20 sec. 94°C
KCl 50 mM Annealing 30 sec. 62°C
Taq pol 2 U Extension 30 sec. 72°C
H2O (distilled) 9 ll Final extension 5 min. 72°C
DNA 0.5–1 lg Hold – 4°C –
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phism genotypes. P-values less than 0.05 were considered statistically
significant.
Results
In this study, a total of 257 individuals were examined. Of which 206
of them were acute stroke patients (aaa mean age 58.6610.6 years)
and 51 were healthy persons, comparable by age and gender. DNA
was successfully extracted from peripheral leucocytes in 206 acute
stroke patients (94 female and 112 male) and 51 healthy persons (35
female and 16 male).
The genotype frequencies and allele rates for the AT1 gene
A1166C polymorphism in the control group, all patients group and
the patient subgroups are given in Table 2. There was no statistically
significant difference in genotype frequencies between the control
group and the patient group (P > 0.05).
There was no statistically significant difference between the stroke
subtypes (P > 0.05) in genotype and allele frequencies. Genotype
and allele frequencies, however, showed a significant difference
(P < 0.001) in the control and the patient groups.
Individual features of patients and controls are shown in Table 3
according to the AT1 gene A1166C polymorphism genotypes. There
was no association between A1166C genotypes and individual fea-
tures. However, in the heart disease control group, there was no
association between the A1166C genotype of the AT1 gene and indi-
vidual features (P = 0.09).
Some physiological and clinical parameters of patient and con-
trols are presented in Table 4 according to genotype. There was no
association between A1166C genotypes of the AT1 gene and these
parameters.
The distribution of the A1166C polymorphism in the AT1 gene in
patients and controls are given in Table 5 according to gender. There
was no significant difference between the females and males of the
control group.
Fig. 1 RFLP analysis of the A1166C mutation. The prototype fragment
has 410 bp. The figure demonstrates M: Marker, AC: heterozygous
mutant (1. sample), AA: homozygous normal (2, 3, 4, 5, 6, 7, 8, 9, 10
samples) genotypes.
Table 2 Distribution of genotypes and alleles according to stage of controls, total patients and patient subgroups
Genotypes Alleles
AA, n (%) AC, n (%) A, n (%) C, n (%)
Control 43 (84.3) 8 (15.7) P < 0.001†b 94 (92.15) 8 (7.85) P < 0.001†d
Patients 194(94.2) 12 (5.8) P < 0.001†b 400 (97) 12 (3) P < 0.001†d
P > 0.05*a P > 0.05*a P > 0.05*c P > 0.05*c
Genotypes Alleles
Stroke subtypes AA, n (%) AC, n (%) A, n (%) C, n (%)
Large vessel disease 46 (96) 2 (4) 94 (98) 2 (2)
Small vessel disease (lacunae) 56 (93) 4 (7) 116 (97) 4 (3)
Cardioembolism 29 (94) 2 (6) 60 (97) 2 (3)
Transient ischaemic attacks (TIA) 7 (78) 2 (22) 16 (89) 2 (11)
Other ischaemic strokes 10 (100) 0 (0) 20 (100) 0 (0)
Haemorrhage 46 (96) 2 (4) 94 (98) 2 (2)
P > 0.05‡ P > 0.05‡
*Two Proportions z test.
†One Proportion exact test, a: Control versus Patient in each Genotypes, b: AA versus AC in each groups, c: Control versus Patient in each
Alleles, d: A versus C in each groups.
‡Pearson Exact Chi-Square.
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Discussion
Some recent studies have presented that there is the genetic predis-
position to the development of stroke. However, some studies provide
contradictory evidence, either in favour or not of a correlation
between the A1166C polymorphism and stroke.
In this study, we analysed the distribution of AT1 gene A1166C
polymorphism genotypes in acute stroke patients in Turkey to assess
its possible role in the pathogenesis of acute stroke.
When we examined every patient and control in our study for their
genotype of the AT1 gene at the A1166C position, we found the fol-
lowing: 84% AA and 16% AC for controls and 94% AA and 6% AC for
patients. There was no statistically significant difference between the
control group and the patient group in terms of genotype and allele
frequency.
In two studies of 308 ischaemic stroke patients, Szolnoki et al.
reported that the angiotensin II type 1 receptor A1166C polymor-
phism is associated with the development of small vessel ischaemic
stroke [13] and increased risk of ischaemic stroke in hypertensive
smokers [14]. In a study of 215 ischaemic stroke patients, aaaRub-
attu et al. reported a predisposing role of an AT1 gene variant in the
development of ischaemic stroke. In particular, the AT1 gene variant
exerted a major impact on ischaemic stroke occurrence in the
presence of hypertension [16]. In a study of 152 type 2 diabetic
patients with strokes, Zhang et al. reported a synergistic effect of the
angiotensin II type 1 receptor A1166C and ACE I/D gene polymor-
phisms on the occurrence and development of stroke in type 2
diabetic patients in China [20].
Henskens et al. reported that AT1R A1166C polymorphism is
significantly associated with subcortical white matter lesions
(WMLs). In addition, they have reported that when using the AA
genotype as the reference category, the CC genotype of the AT1R
A1166C polymorphism is inversely associated with the volume of
subcortical WMLs [19].
Mollsten et al. have determined that individuals with the AA geno-
type of the AT1R gene are at increased risk of ischaemic stroke com-
pared with those with the AC and CC genotypes. They have reported
that A1166C polymorphism in the angiotensin II receptor gene is
associated with ischaemic stroke [21].
Takami et al. reported that AT1R polymorphism was signifi-
cantly associated with the number of lacunae in the basal ganglia
and whole brain regions and with periventricular hyperintensity
grade in the younger population. They have reported that AT1
polymorphisms are independent genetic risk factors for lacunar
infarction [22].
Brenner et al have determined 1166 AA genotype frequency as
49.2%, AC genotype frequency as 41.6%, CC genotype frequency as
9.2% for patients; and AA genotype frequency as 56.0%, AC genotype
frequency as 34.4% and CC genotype frequency as 9.6% for control
group. They have reported that 1166C allele is a weak association of
brain infarction [3].
Sipahi et al. have determined 1166 AA genotype frequency as
58%, AC genotype frequency as 34.6%, CC genotype frequency as
7.4% for patients; and AA genotype frequency as 60.1%, AC genotype
frequency as 35.7% and CC genotype frequency as 4.2% for control
group. Similar to our findings, they have also reported no difference
among the stroke subgroups regarding the distribution of AT1R
(A1166C) polymorphisms [15].
In a study of 129 ischaemic stroke patients, aaaMizuno et al.
reported that the angiotensin II type 1 receptor A1166C polymor-
phism showed no significant effect on ischaemic stroke, similar to
our findings in this study. However, the ACE polymorphism has a
role in lacunar infarction that is independent from hypertension
[2].
Wiklund et al. have determined 1166 AA genotype frequency
as 59%, AC genotype frequency as 34%, CC genotype frequency
as 17%, for ischaemic stroke patients; 1166 AA genotype fre-
quency as 50%, AC genotype frequency as 39%, CC genotype
frequency as 12%, for haemorrhagic stroke patients and AA
genotype frequency as 50%, AC genotype frequency as 42% and
TT genotype frequency as 7% for control group. They have
reported that individuals carrying the AA genotype of the angio-
tensin II type 1 receptor A1166C polymorphism to be at some-
Table 3 Distribution of AT1 gene A1166C polymorphism genotypes
according to individual features of controls and patients
Individual features Groups AA (%) AC (%) Statistic
Hypertension Controls 92.3 7.7 *P = 0.003
Patients 92 8 *P < 0.001
Smoking Controls 87.5 12.5 *P = 0.035
Patients 96 4 *P < 0.001
Alcohol use Controls 0 0 †
Patients 92.9 7.1 *P = 0.001
History of stroke Controls 0 0 †
Patients 85.7 14.3 *P < 0.001
Trauma Controls 100 0 †
Patients 95 5 *P < 0.001
Heart disease Controls 77.8 22.2 *P = 0.09
Patients 92.1 7.9 *P < 0.001
Vessel disease Controls 0 0 †
Patients 95.1 4.9 *P < 0.001
Diabetes Controls 81.8 18.2 *P = 0.033
Patients 93.9 6.1 *P < 0.001
Renal disease Controls 0 0 †
Patients 91.7 8.3 *P = 0.003
*One Proportion exact test.
†Could not be statistically analysed because of genotype quantity.
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what higher risk of future stroke as compared with the AC and
CC genotypes [1].
In conclusion, although there are various population studies
showing significant association between AT1 gene A1166C poly-
morphism and susceptibility to stroke, our findings suggest that
the AT1 gene A1166C polymorphism is not associated with sus-
ceptibility to acute stroke in Turkish population that might be
due to particular genetic structure of Turkish population. It also
clarifies a causality role to polymorphisms for the multifactorial
nature of stroke pathogenesis, in which many genetic variants
could contribute, together with environmental and the interactions
of other genes. As a result, further studies in larger populations
are required to clarify the interactions of the A1166C polymor-
phism with stroke due to the different findings from various pop-
ulations.
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